Market Cap 226.85M
Revenue (ttm) 90.40M
Net Income (ttm) -126.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.34%
Debt to Equity Ratio -2.63
Volume 1,478,900
Avg Vol 1,513,984
Day's Range N/A - N/A
Shares Out 46.11M
Stochastic %K 87%
Beta 0.40
Analysts Strong Sell
Price Target $20.29

Latest News on URGN

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd.

May 29, 2025, 3:00 PM EDT - 7 days ago

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd.


Did UroGen Pharma Ltd. (URGN) Mislead Investors?

May 28, 2025, 9:15 AM EDT - 8 days ago

Did UroGen Pharma Ltd. (URGN) Mislead Investors?